Clinical Trials
5 trialsNCT05283720 2026-05-06
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT04578600 2025-04-24
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Phase 1 Completed
NCT01254578 2017-09-25
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
Phase 1 Completed
NCT01419795 2017-07-27
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT02281279 2016-08-11
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Withdrawn